Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

Monte Rosa Therapeutics, Inc.

GLUE Nasdaq SEC CIK 1826457
Follow Monte Rosa Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $9M −61.3% vs same quarter last year
Net income −$43.4M −253% vs same quarter last year
EPS, diluted -
Operating cash flow −$44.1M −27.1% vs same quarter last year
Revenue by quarter
$9.2M
$60.6M
$84.9M
$23.2M
$12.8M
$2.8M
$4.2M
$9M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$123.7M−$38.6M
FY24$75.6M−$72.7M
FY23$0−$135.4M
FY22-−$108.5M
FY21-−$74M
FY20-−$35.9M
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0$50MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$27.5M
FY24$38M
FY23−$62.8M
FY22−$105.4M
FY21−$69.1M
FY20−$26.4M
FY19-

News

No stories filed under Monte Rosa Therapeutics yet - coverage appears here as the news feed clusters it.